BrainChip (BRN) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
10 Jun, 2026Executive summary
Focused on advancing customer engagements toward commercialization, including a major collaboration with Frontgrade Gaisler to integrate neuromorphic AI into space-grade microprocessors.
Introduced new CTO and outlined a new technology and product development strategy, emphasizing the commercialization potential of the proprietary TENNs algorithm.
Closed the Brainchip Research Institute in Perth to consolidate R&D under the CTO, reducing expenses and headcount.
Expanded the University AI Accelerator Program, adding Penn State University to a growing list of partners.
Financial highlights
Ended the June 2024 quarter with US$10.9M in cash, down from US$12.9M in the prior quarter.
Net operating cash outflows were US$3.9M, an improvement from US$4.4M in the previous quarter.
Cash inflow from customers was US$0.05M, compared to US$0.09M in the prior quarter.
Total payments to suppliers and employees were US$4.1M, slightly lower than US$4.9M in the prior quarter.
Cash used for operating activities included US$337K in payments to directors.
Outlook and guidance
Management remains optimistic about future sales based on active customer engagements and interest, despite long sales cycles.
Estimated quarters of funding available is 3.0, indicating sufficient liquidity for near-term operations.
Latest events from BrainChip
- Cash outflows improved as AKD1500 production scaled and new commercial partnerships expanded.BRN
Q4 2026 - AGM focused on product innovation, commercial growth, and shareholder engagement challenges.BRN
AGM 2025 - Strategic growth, new edge AI products, and governance dominated, with robust shareholder engagement.BRN
AGM 2026 - Revenue up 72% and net loss reduced, with strong capital raises and edge AI focus for 2025.BRN
H2 2024 - Revenue up 374% to $1.89M, net loss narrows, AKD1500 enters production, capital base strengthened.BRN
H2 2025 - Cash position strengthened and new partnerships drive momentum for neuromorphic AI products.BRN
Q4 2025 - Cash balance rose to $13.9M as AKD1500 enters volume production, backed by new capital and partnerships.BRN
Q3 2025 - $35M placement and $2M SPP to accelerate edge AI commercialization and product expansion.BRN
Investor Presentation - Edge AI and neuromorphic solutions drive growth across defense, healthcare, and consumer markets.BRN
Investor Presentation